Value proposition

Discovering drugs that create neoantigens

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.

Biotechnology, Drug Discovery, Small Molecule Therapeutics, Oncology, Immuno-oncology, Cancer, Genetics, and Translational Medicine